
    
      This is a multicenter registry study of IgG4-RD patients. Newly diagnosed IgG4-RD patients
      will be recruited from allover the China. Inclusion criteria: patients with definite,
      probable, or possible IgG4-RD according to the 2011 comprehensive diagnostic criteria for
      IgG4-RD will be recruited. Exclusion criteria: patients with malignancy or other autoimmune
      diseases are excluded.

      The data will be uploaded through the platform of Chinese Rheumatology Information Platform.
      Demographic data, initial symptoms, disease duration, history of allergy, and physical
      examination, organ involvements, laboratory findings, radiological and pathological results,
      as well as treatment, side effects will be recorded.

      This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All
      patients will signe informed consent.

      Statistical Analysis: All parameters are described in the standard summary statistics,
      including mean, standard deviation, minimum, and maximum. All statistical analyses will be
      performed by SPSS.

      Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IgG4-RD
      patients. The secondary endpoints including the demographic features,laboratory
      characteristics, immunological tests, imaging and pathological features, in addition, the
      treatment and prognosis of the disease.
    
  